Literature DB >> 17523150

Body fat distribution and metabolic variables in patients with neonatal progeroid syndrome.

Brendan O'Neill1, Vinaya Simha, Vani Kotha, Abhimanyu Garg.   

Abstract

Neonatal progeroid syndrome (NPS), also known as Wiedemann-Rautenstrauch Syndrome, is a rare autosomal recessive disorder characterized by accelerated aging and lipodystrophy from birth. Affected children have extreme intrauterine growth retardation, poor postnatal weight gain, and characteristic facial dysmorphic features such as a triangular shape, pinched nose, pseudohydrocephalus with wide fontanelles and prominent subcutaneous (sc) veins. Generalized loss of sc fat has been reported as a cardinal feature; however, the pattern of fat loss and its association with insulin resistance and its metabolic complications have not been systematically studied. The aim of the current study was to examine body fat distribution and body composition in two girls with NPS using anthropometric measures, whole-body magnetic resonance imaging (MRI) and dual energy X-ray absorptiometry (DEXA), and to assess metabolic complications such as hyperinsulinemia and dyslipidemia. Both the girls (aged 17 years and 10 years, respectively) had generalized paucity of sc fat on physical examination. However, measurements of skin-fold thickness revealed that sc fat was decreased over the extremities, but preserved over the chest and abdomen. MRI studies confirmed the presence of normal amounts of sc truncal fat, and marked loss of fat from the face and distal extremities. Striking fat loss was also noted in the paravertebral and lateral gluteal regions. Interestingly, body composition analysis with DEXA scan revealed a marked reduction in both the fat and lean tissue mass. Fasting glucose, lipids and insulin levels were not elevated. We conclude that patients with NPS do not have generalized lipodystrophy as previously reported, but fat loss is confined to the face, distal extremities, and possibly the paravertebral and lateral gluteal regions. Metabolic abnormalities related to insulin resistance are also uncommon in this condition. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17523150     DOI: 10.1002/ajmg.a.31840

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  8 in total

1.  Wiedemann-Rautenstrauch syndrome: first Indian case.

Authors:  Meenu Pandey; Neeraja Gupta; Madhulika Kabra; Ajay Kumar; Vikram Datta; Arvind Saili
Journal:  Indian J Pediatr       Date:  2011-06-01       Impact factor: 1.967

2.  Increased plasma asprosin levels in patients with drug-naive anorexia nervosa.

Authors:  Yanran Hu; Yixiang Xu; Yuchen Zheng; Qing Kang; Zhongze Lou; Qiang Liu; Han Chen; Yunxin Ji; Lei Guo; Chen Chen; Liemin Ruan; Jue Chen
Journal:  Eat Weight Disord       Date:  2020-02-05       Impact factor: 4.652

3.  Bi-allelic POLR3A Loss-of-Function Variants Cause Autosomal-Recessive Wiedemann-Rautenstrauch Syndrome.

Authors:  Jennifer A Wambach; Daniel J Wegner; Nivedita Patni; Martin Kircher; Marcia C Willing; Dustin Baldridge; Chao Xing; Anil K Agarwal; Samantha A Schrier Vergano; Chirag Patel; Dorothy K Grange; Amy Kenney; Tasnim Najaf; Deborah A Nickerson; Michael J Bamshad; F Sessions Cole; Abhimanyu Garg
Journal:  Am J Hum Genet       Date:  2018-11-07       Impact factor: 11.025

4.  Asprosin, a Fasting-Induced Glucogenic Protein Hormone.

Authors:  Chase Romere; Clemens Duerrschmid; Juan Bournat; Petra Constable; Mahim Jain; Fan Xia; Pradip K Saha; Maria Del Solar; Bokai Zhu; Brian York; Poonam Sarkar; David A Rendon; M Waleed Gaber; Scott A LeMaire; Joseph S Coselli; Dianna M Milewicz; V Reid Sutton; Nancy F Butte; David D Moore; Atul R Chopra
Journal:  Cell       Date:  2016-04-14       Impact factor: 41.582

Review 5.  Asprosin, a C-Terminal Cleavage Product of Fibrillin 1 Encoded by the FBN1 Gene, in Health and Disease.

Authors:  Mehmet Akif Ovali; Ibrahim Bozgeyik
Journal:  Mol Syndromol       Date:  2022-02-08

Review 6.  Energy Regulation Mechanism and Therapeutic Potential of Asprosin.

Authors:  Jennifer G Hoffmann; Wei Xie; Atul R Chopra
Journal:  Diabetes       Date:  2020-04       Impact factor: 9.461

7.  Asprosin is a centrally acting orexigenic hormone.

Authors:  Clemens Duerrschmid; Yanlin He; Chunmei Wang; Chia Li; Juan C Bournat; Chase Romere; Pradip K Saha; Mark E Lee; Kevin J Phillips; Mahim Jain; Peilin Jia; Zhongming Zhao; Monica Farias; Qi Wu; Dianna M Milewicz; V Reid Sutton; David D Moore; Nancy F Butte; Michael J Krashes; Yong Xu; Atul R Chopra
Journal:  Nat Med       Date:  2017-11-06       Impact factor: 53.440

8.  Plasma Asprosin Concentrations Are Increased in Individuals with Glucose Dysregulation and Correlated with Insulin Resistance and First-Phase Insulin Secretion.

Authors:  Yuren Wang; Hua Qu; Xin Xiong; Yuyang Qiu; Yong Liao; Yingchun Chen; Yi Zheng; Hongting Zheng
Journal:  Mediators Inflamm       Date:  2018-03-20       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.